Veeva Systems Inc. (VEEV)
Veeva Systems provides the digital backbone for the life sciences industry, helping pharmaceutical companies manage clinical trials and regulatory data.
Is Veeva Systems Inc. a good stock for a UK beginner?
The honest version: Veeva Systems provides the digital backbone for the life sciences industry, helping pharmaceutical companies manage clinical trials and regulatory data.
Over about 2 years to 2026-07-31. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Veeva becomes the essential global standard for all medical data management.
Technological obsolescence or a major shift in how drugs are developed.
What does Veeva Systems Inc. do?
Think of Veeva as the specialist software provider that helps drug companies organise the complex paperwork and data required to bring new medicines to market. It charges these companies subscription fees to use its cloud-based platforms. What matters most here is whether they can keep expanding their customer base while holding off larger, general-purpose tech giants.
On our factor screen it looks strongest on quality and growth, and weakest on income.
- !Pays no dividend - the whole return rides on the share price
- ✓Growing - revenue up about 16% over the year
- ✓Very profitable - turns about 28% of sales into profit
- !High P/E of 36 - big growth is already priced in
- ✓Low debt - a sturdier balance sheet
- Quality screens high (80/100)
- High profit margins typical of successful software businesses
- Strong position in a niche, essential industry
- Recurring revenue model provides predictable income
- Income screens low (16/100)
- Heavy reliance on the pharmaceutical industry's spending habits
- Potential for large tech competitors to enter the space
- Data security and privacy concerns in the medical field
What do Veeva Systems Inc.'s numbers mean?
How much money does Veeva Systems Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Veeva Systems Inc. pay a dividend?
No - Veeva Systems Inc. doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
When does Veeva Systems Inc. report earnings, and how did recent quarters go?
Veeva Systems Inc. is next scheduled to report on about 2026-09-02 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-06-03 | $2.14 | $2.24 | Beat +5% |
| 2026-03-04 | $1.94 | $2.06 | Beat +6% |
| 2025-11-20 | $1.95 | $2.04 | Beat +5% |
| 2025-08-27 | $1.90 | $1.99 | Beat +5% |
| 2025-05-28 | $1.74 | $1.97 | Beat +13% |
| 2025-03-05 | $1.58 | $1.74 | Beat +10% |
Across the last 6 quarters here, Veeva Systems Inc. came in ahead of what analysts expected 6 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for Veeva Systems Inc.?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Veeva Systems Inc.?
How many points the write-up makes each way — a balance check, not a score or verdict.
- High profit margins typical of successful software businesses
- Strong position in a niche, essential industry
- Recurring revenue model provides predictable income
- No dividend payments for those seeking regular income
- High valuation relative to current earnings
- Significant share price decline over the past year
- Heavy reliance on the pharmaceutical industry's spending habits
- Potential for large tech competitors to enter the space
- Data security and privacy concerns in the medical field
The write-up's own warning lights — if these start happening, the case above changes.
- A sustained drop in pharmaceutical research and development spending
- A major security breach that damages the company's reputation
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.